1. CHD6 is highly expressed in colorectal cancer (CRC) and its knockdown inhibits cancer cell proliferation, migration, invasion, and tumorigenesis.
2. Aberrant EGF signals promote the stability of CHD6 by diminishing ubiquitin-mediated degradation.
3. CHD6's chromatin remodeler activity engages in binding Wnt signaling transcription factor TCF4 to facilitate the transcriptional expression of TMEM65, a mitochondrial inner membrane protein involved in ATP production and mitochondrial dynamics.
The article is generally reliable and trustworthy as it provides evidence for its claims through experiments conducted on mice models as well as patient-derived xenografts of CRC. The authors also provide evidence for their claims through data from the TCGA Colorectal Adenocarcinoma database. Furthermore, they provide detailed explanations for their findings which makes it easier to understand the mechanisms behind them.
However, there are some potential biases that should be noted. Firstly, the authors do not explore any counterarguments or alternative explanations for their findings which could lead to a one-sided reporting of the results. Secondly, there is no mention of possible risks associated with targeting CHD6-TMEM65 axis which could be important to consider when discussing potential interventions for cancer treatment. Lastly, there is no discussion about how this research could be applied in clinical settings which could be beneficial to include in order to make the article more comprehensive.